menu
    • menu

    Company profile for KalVista Pharmaceuticals

    NEW Drugs in Dev: 3
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed...
    KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KalVista PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    55 Cambridge Pkwy Cambridge, Massachusetts 02142
    Telephone
    Telephone
    1 (857) 999 0075
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kalvista.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kalvista-pharmaceuticals-limited/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/kalvista?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kalvista Pharma To Present At Investor Conferences
    Kalvista Pharma To Present At Investor Conferences

    25 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-25/kalvista-pharmaceuticals-to-present-at-upcoming-investor-conferences

    PHARMIWEB
    25 Feb 2026
    Share Share
    KalVista Presents EKTERLY Data at 2026 AAAAI Meeting
    KalVista Presents EKTERLY Data at 2026 AAAAI Meeting

    12 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-12/kalvista-pharmaceuticals-to-present-ekterly-sebetralstat-data-at-the-2026-american-academy-of-all

    PHARMIWEB
    12 Feb 2026
    Share Share
    KalVista Pharma Grants Inducements Under Nasdaq Rule 5635(c)(4)
    KalVista Pharma Grants Inducements Under Nasdaq Rule 5635(c)(4)

    03 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-03/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4

    PHARMIWEB
    03 Feb 2026
    Share Share
    JPM26: Kalvista's HAE Win Is A 'Tale Of Two Markets'
    JPM26: Kalvista's HAE Win Is A 'Tale Of Two Markets'

    21 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/jpm26-kalvistas-hae-win-is-a-tale-of-two-markets

    BIOSPACE
    21 Jan 2026
    Share Share
    KalVista Pharma: Strong EKTERLY Launch, 2025 Revenue Outlook
    KalVista Pharma: Strong EKTERLY Launch, 2025 Revenue Outlook

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108509630/en/KalVista-Pharmaceuticals-Provides-Update-on-Strong-EKTERLY-Launch-with-Preliminary-Fourth-Quarter-and-Full-Year-2025-Revenue-Results

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Japan Approves KalVista's EKTERLY as First Oral HAE Therapy
    Japan Approves KalVista's EKTERLY as First Oral HAE Therapy

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251222393408/en/KalVista-Pharmaceuticals-Announces-Approval-of-EKTERLY-sebetralstat-in-Japan-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema

    BUSINESSWIRE
    22 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search